Lupin shares slipped over 3 percent intraday Monday despite its Pithampur unit-3 in Indore receiving Establishment Inspection Report from the US health regulator.
The inspection at this facility was conducted between June 12 and June 16, 2017.
"This was a pre-approval inspection for Albuterol Sulfate Inhalation product," the pharma major said.
Pithampur (Unit 3) facility manufactures dermatological products, dry product inhalers and metered dose inhalers.
Meanwhile, last week Lupin announced completion of USFDA inspections at its Mandideep location which houses the company's cardiovascular Pril API facilities, Cephalosporin API facilities and Cephalosporin solid oral dosage form facility.
These inspections were carried out between November 26 and December 4, 2018.
The inspection at Unit-2, the Cardiovascular Pril" API facilities closed with 4 observations and Unit-I, the Cephalosporin facilities closed with 10 observations for the Cephalosporin API facilities and 8 observations for the Cephalosporin solid oral dosage form facility.
"The observations are largely procedural in nature with some gaps identified in the aseptic processing areas of the Cephalosporin API block and the company is confident of addressing them satisfactorily," the company had said.
At 14:12 hours IST, the stock was quoting at Rs 822.55, down Rs 17.35, or 2.07 percent on the BSE.
We provide you sure shot Commodity & Equity Market Tips, Intraday tips, share market tips, Mcx bullion tips, Mcx tips, Crude tips, Stock tips, Future and Cash tips with Technical & Fundamental Research.
Visit: www.ripplesadvisory.com
Contact us @ +91-9644405056
Source: Moneycontrol
No comments:
Post a Comment